Use of antisense oligonucleotide in Progressive supranuclear palsy
Theme Group:
Clinical Trials and Therapeutics
Funding:
Phase 1 clinical trial funded by Novartis
About the project:
Phase 1 first in human clinical trial in patients with progressive supranuclear palsy.
Key iDeAC expertise:
Dr Boyd Ghosh
Clinical Trials
Related projects:
Use of antisense oligonucleotide in Progressive supranuclear palsy
Treating impulsivity in people with progressive supranuclear palsy
Using electronic patient records to examine patient outcomes in Dementia with Lewy bodies
Combining Memantine and Cholinesterase inhibitors in Lewy body dementia treatment trial (COBALT)
Phase 1 trial of bepranemab in progressive supranuclear palsy
Permeability of the blood-brain barrier in Alzheimer’s disease (PEBBAL) measured using dynamic contrast-enhanced MRI: a pilot study
Diagnostic biomarkers of gut microbiome-associated phenotypes predictive of healthy aging and neurodegenerative disease (BIO-AGE)